Home › Funds › Virtus › Virtus KAR Health Sciences Fund
Fund family: Virtus · Filed by Virtus Investment Trust (CIK 867297) · SEC series S000007977
Share classes and tickers: HLHIX (C000150255), RAGHX (C000021683)
“With management” counts the items where the fund’s own filing gives management’s recommendation (FOR or AGAINST): 268 with, 11 against, 0 abstentions (not counted as with management). Shareholder proposals: 5 FOR, 6 AGAINST, 0 abstained, by the filing’s own vote-source field.
The same two figures as Virtus’s manager page (46,367 ballot items across 77 funds and accounts), counted the same way for this fund.
| 2025-2026 | This fund | Items | Virtus | Items |
|---|---|---|---|---|
| Voted FOR the board's own proposals (directors, pay, auditor, capital, transactions, fund matters) | 98.1% | 262 | 93.4% | 39,201 |
| Backed environmental and social shareholder proposals at US companies | n/a | 4 | 8.6% | 1,030 |
Each ballot item this fund voted is set against the votes of the other Virtus funds and accounts on the same item (same meeting, same proposal): “most funds” is a strict majority of at least three of them, FOR against AGAINST, WITHHOLD or ABSTAIN, with split votes and items not voted left out. Funds in one family can follow separate voting policies, for example ESG funds, sub-advised funds and funds using pass-through voting.
Voted the same way as most Virtus funds on all 201 items where a comparison was possible.
The same votes as “with management” above, by the sector of the company voted on. 95.3% of this fund’s 279 such votes could be given a sector; the other 13 (4.7%) are at companies without one and are not in the table.
| Sector | Votes | Against management | Share |
|---|---|---|---|
| Health Care | 214 | 11 | 5.1% |
| Industrials | 38 | 0 | 0.0% |
| Consumer Discretionary | 14 | 0 | 0.0% |
| Proposal type | Items | Against management |
|---|---|---|
| Director Elections | 206 | 0 |
| Audit-related | 26 | 0 |
| Say-on-Pay | 24 | 0 |
| Corporate Governance | 11 | 7 |
| Compensation | 5 | 0 |
| Capital Structure | 2 | 0 |
| Environment or Climate | 2 | 2 |
| Other Social Issues | 2 | 2 |
| Shareholder Rights and Defenses | 2 | 0 |
Position = shares voted × a recent share price, for US-listed shares of companies with a page on this site; an estimate for ranking only.
| Company | Meeting | Est. position | Items | Against mgmt |
|---|---|---|---|---|
| Eli Lilly and Company | May 4, 2026 | $38M | 10 | 2 |
| McKesson Corporation | July 30, 2025 | $19M | 14 | 0 |
| West Pharmaceutical Services, Inc. | May 4, 2026 | $13M | 14 | 1 |
| AbbVie Inc. | May 8, 2026 | $12M | 8 | 1 |
| Vertex Pharmaceuticals Incorporated | May 13, 2026 | $11M | 14 | 1 |
| Merck & Co., Inc. | May 26, 2026 | $11M | 18 | 3 |
| Mettler-Toledo International Inc. | May 7, 2026 | $10M | 11 | 0 |
| Thermo Fisher Scientific Inc. | May 20, 2026 | $10M | 13 | 0 |
| Meeting | Company | Proposal | Fund | Mgmt |
|---|---|---|---|---|
| May 4, 2026 | Eli Lilly and Company | Shareholder proposal to adopt a policy and amend the bylaws to require an independent board chair. Shareholder proposal | For | Against |
| May 4, 2026 | Eli Lilly and Company | Shareholder proposal to prepare an annual lobbying report. Shareholder proposal | Against | For |
| May 4, 2026 | West Pharmaceutical Services, Inc. | Shareholder proposal regarding an independent Board Chair policy. Shareholder proposal | For | Against |
| May 8, 2026 | AbbVie Inc. | Stockholder Proposal - to Adopt a Policy to Require an Independent Chair Shareholder proposal | For | Against |
| May 13, 2026 | Vertex Pharmaceuticals Incorporated | Shareholder proposal, if properly presented at the meeting, regarding shareholder right to act by written consent. Shareholder proposal | For | Against |
| May 26, 2026 | Merck & Co., Inc. | Shareholder proposal regarding a report on DEI risks in federal contracting. Shareholder proposal | Against | For |
| May 26, 2026 | Merck & Co., Inc. | Shareholder proposal regarding a report on healthcare coverage gaps. Shareholder proposal | Against | For |
| May 12, 2026 | IDEXX Laboratories, Inc. | Shareholder Proposal to Give Shareholders the Ability to Call for a Special Shareholder Meeting (Proposal Six). Shareholder proposal | For | Against |
| May 19, 2026 | Amgen Inc. | Stockholder proposal to require an independent board chairman. Shareholder proposal | Against | For |
| June 1, 2026 | UnitedHealth Group Incorporated | If properly presented at the 2026 Annual Meeting of Shareholders, the shareholder proposal requesting the adoption of a policy to require any Board Chair to be independent. Shareholder proposal | Against | For |
280 ballot items at 24 meetings in 2025-2026. Download all votes (CSV)
Recent votes against management’s recommendation at large companies.
In the 2025-2026 proxy season, Virtus KAR Health Sciences Fund (HLHIX) voted at 24 shareholder meetings of 24 companies, on 280 ballot items in all. Where management made a recommendation, the fund followed it on 96.1% of the items and voted against it 11 times. Its most frequent area of disagreement was corporate governance (7 of its votes against management). It voted on 11 shareholder proposals. It voted FOR the board's own proposals more often than Virtus's funds as a whole (98.1% against 93.4%). It voted the same way as most Virtus funds on every item where a comparison was possible.
Every figure is derived from the fund’s own Form N-PX filings with the SEC, read item by item: one ballot item is the fund’s vote on one proposal at one meeting, and an item filed twice in the season is counted once. Percentages count items, never shares. A season is published only with at least 250 ballot items at 15 meetings. Built November 18, 2026; the family figures are those of Virtus’s manager page. The interactive database shows the same votes company by company, with every other fund that voted.